Bio-Rad Showcases Compatibility of SEQuoia™ RNA Library Preparation Kits with New Innovative Sequencers at AGBT 2023

SEQuoia Express Stranded RNA Library Prep Kit

SEQuoia Express Stranded RNA Library Prep Kit

HERCULES, Calif.—Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, has developed partnerships with leading innovative next-generation sequencing (NGS) instrument providers and announces compatibility of the SEQuoia RNA Sequencing Library Preparation portfolio on new state-of-the-art sequencers, including the Singular Genomics G4™ System.

Recent compatibility studies show that the SEQuoia Complete Stranded RNA Library Prep Kit and the SEQuoia Express Stranded RNA Library Prep Kit offer unbiased transcriptome profiling during RNA sequencing by capturing a broad range of RNA subtypes in a single workflow, whether working with low or high input RNA, when used with the Singular Genomics G4 System and other sequencing systems. The SEQuoia Express Stranded RNA Library Prep Kit offers the additional benefit of a highly efficient 3-tube, 3-hour workflow for detection of long RNAs when used on the G4 System and other sequencing systems.

“We’re very enthusiastic about the partnership with Bio-Rad. The combination of the G4 Sequencing Platform and SEQuoia RNA library preparation provides end users an unmatched combination of speed, flexibility, and accuracy,” states Jorge Velarde, Senior Vice President of Corporate Development and Strategy at Singular Genomics™

“Expanding access to leading technologies in RNA sequencing requires RNA library preparation chemistries that offer the highest-quality sequencing outcomes. These partnerships will ensure that our customers can use new platforms in a plug-and-play format and readily obtain high-performing data,” said Steven Blakely, Senior Director for the Gene Expression Business, Bio-Rad. “We will continue to seek out other providers of RNA sequencing technologies to investigate further synergies with SEQuoia workflows,” he added.

Bio-Rad will be attending the Advances in Genome Biology and Technology (AGBT) General Meeting in Hollywood, Florida, February 6–9, 2022. Join the Bio-Rad speaker sessions on February 8 and 9 (Presidential Suite 3131) to find out more about the results of the collaboration using the company’s novel RNA-Seq Library Preparation Kits, and view its range of genomics solutions on February 7 during its Chinese Lantern Festival Celebration (Presidential Suite 3131).

Key Bio-Rad events planned for conference attendees:

  • Wednesday, February 8, 8 AM EST: SEQuoia RNA Library Prep Kits on the Singular Genomics G4TM Sequencer
    Learn how SEQuoia Complete and SEQuoia Express library preparation on the Singular Genomics G4 Sequencer can provide data quality that rivals an industry standard.
  • Wednesday, February 8, 8:15 AM EST: SEQuoia Complete Kit Enables Comprehensive Transcriptome Profiling with FFPE Samples
    Capture more of the transcriptome from poor-quality FFPE RNA samples using the SEQuoia Complete Kit in a single workflow.
  • Thursday, February 9, 8 AM EST: SEQuoia RNA Library Prep Kits on a New Benchtop Sequencer
    Unlock rapid and unbiased transcriptome profiling with SEQuoia Complete and SEQuoia Express RNA Library Preparation Kits on the new platform.
  • Thursday, February 9, 8:15 AM EST: Advanced Six-Color Multiplexing on the QX600™ Droplet Digital™ PCR System
    See how to quantify multiple targets in digital PCR with high accuracy, reproducibility, and sensitivity.

Please visit to learn more about the SEQuoia RNA-Seq Library Preparation Kits.

BIO-RAD, DROPLET DIGITAL, SEQuoia and QX600 are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. Singular Genomics and G4 are trademarks of Singular Genomics Systems, Inc. All trademarks used herein are the property of their respective owner.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With 70 years of focus on quality and customer service, our products advance the scientific discovery process and improve healthcare. Our customers are universities, research institutions, hospitals, biotechnology and pharmaceutical companies, as well as public health and commercial laboratories including food safety and environmental quality testing facilities. Based in Hercules, California, Bio-Rad has a global network of operations with approximately 8,200 employees worldwide and $2.9 billion in revenues in 2021. For more information, please visit

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include the duration and severity of the COVID-19 pandemic, supply chain risks, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Media Contacts:
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
+1 510-356-7909

Zyme Communications
Esmé Walters
+44 (0) 7737 543244